Pharmacologically targeting WEE1 (WEE1 inhibitor) combined with androgen receptor pathway inhibitor or glucocorticoid receptor modulators resensitized SOX2-positive PCa cells to NHRSI in vitro, and the combination of WEE1 inhibitor and androgen receptor pathway inhibitor substantially retarded tumor growth in vivo (Fig. 3B). Here, SOX2 is linked to neoplasm.